Regulatory Verification by Health Canada of Content in Recombinant Human Insulin, Human Insulin Analog, and Porcine Insulin Drug Products in the Canadian Market Using Validated Pharmacopoeial Methods Over Nonvalidated Approaches.

HPLC bioanalytical biotherapeutics drug products insulin pharmacopoeia

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
13 Mar 2023
Historique:
pubmed: 14 3 2023
medline: 14 3 2023
entrez: 13 3 2023
Statut: aheadofprint

Résumé

For diabetes mellitus treatment plans, the consistency and quality of insulin drug products are crucial for patient well-being. Because biologic drugs, such as insulin, are complex heterogeneous products, the methods for drug product evaluation should be carefully validated for use. As such, these criteria are rigorously evaluated and monitored by national authorities. Consequently, reports that describe significantly lower insulin content than their label claims are a concern. This issue was raised by a past publication analyzing insulin drug products available in Canada, and, as a result, consumers and major patient organizations have requested clarification. To address these concerns, this study independently analyzed insulin drug products purchased from local Canadian pharmacies-including human insulin, insulin analogs, and porcine insulin-by compendial and noncompendial reversed-phase high-performance liquid chromatography (RP-HPLC) methods. We demonstrated the importance of using methods fit for purpose when assessing insulin quality. In a preliminary screen, the expected insulin peak was seen in all products except two insulin analogs-insulin detemir and insulin degludec. Further investigation showed that this was not caused by low insulin content but insufficient solvent conditions, which demonstrated the necessity for methods to be adequately validated for product-specific use. When drug products were appropriately assessed for content using the validated type-specific compendial RP-HPLC methods for insulin quantitation, values agreed with the label claim content. Because insulin drug products are used daily by over a million Canadians, it is important that researchers and journals present data using methods fit for purpose and that readers evaluate such reports critically.

Sections du résumé

BACKGROUND UNASSIGNED
For diabetes mellitus treatment plans, the consistency and quality of insulin drug products are crucial for patient well-being. Because biologic drugs, such as insulin, are complex heterogeneous products, the methods for drug product evaluation should be carefully validated for use. As such, these criteria are rigorously evaluated and monitored by national authorities. Consequently, reports that describe significantly lower insulin content than their label claims are a concern. This issue was raised by a past publication analyzing insulin drug products available in Canada, and, as a result, consumers and major patient organizations have requested clarification.
METHODS UNASSIGNED
To address these concerns, this study independently analyzed insulin drug products purchased from local Canadian pharmacies-including human insulin, insulin analogs, and porcine insulin-by compendial and noncompendial reversed-phase high-performance liquid chromatography (RP-HPLC) methods.
RESULTS UNASSIGNED
We demonstrated the importance of using methods fit for purpose when assessing insulin quality. In a preliminary screen, the expected insulin peak was seen in all products except two insulin analogs-insulin detemir and insulin degludec. Further investigation showed that this was not caused by low insulin content but insufficient solvent conditions, which demonstrated the necessity for methods to be adequately validated for product-specific use. When drug products were appropriately assessed for content using the validated type-specific compendial RP-HPLC methods for insulin quantitation, values agreed with the label claim content.
CONCLUSIONS UNASSIGNED
Because insulin drug products are used daily by over a million Canadians, it is important that researchers and journals present data using methods fit for purpose and that readers evaluate such reports critically.

Identifiants

pubmed: 36912012
doi: 10.1177/19322968231159360
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19322968231159360

Auteurs

Barry Lorbetskie (B)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Stewart Bigelow (S)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Lisa Walrond (L)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Agnes V Klein (AV)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Shih-Miin Loo (SM)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Nancy Green (N)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Michael Rosu-Myles (M)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Xu Zhang (X)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Huixin Lu (H)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Michel Girard (M)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Simon Sauvé (S)

Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, ON, Canada.

Classifications MeSH